Lupin's arm Nanomi BV completes stake divestment in Kyowa Pharma

Topics Lupin Pharma

Drug maker Lupin on Tuesday said its subsidiary Nanomi BV has completed divestment of its entire stake in Kyowa Pharmaceutical Industry to Japan-based equity fund Unison Capital Partners.

Nanomi BV held 99.82 per cent stake in Japan-based Kyowa, Lupin said in a statement.

Last month, Lupin's board had approved the stake sale in Kyowa for an enterprise value of JPY 57,361 million (around Rs 3,702 crore).

The Mumbai-based drug firm said the transaction generates post tax net cash inflow of around JPY 33,429 million (Rs 2,157.6 crore) and significantly strengthens its consolidated balance sheet.

The deal helps the company pare its net debt from Rs 4,361.8 crore (as on September 30, 2019) to Rs 1,075.3 crore.

The company's net debt to equity ratio now stands at 0.08 as compared to 0.32 earlier.

"This transaction enables us to strengthen our balance sheet and unlock significant value for the company and is aligned with our vision to focus on our key markets and strategic priorities to achieve sustainable growth," Lupin Managing Director Nilesh Gupta said.

The company would continue to selectively monetise its complex generics, biosimilars and specialty assets in Japan with the right partners, including Unison, he added.

Lupin shares were trading 0.87 per cent up at Rs 754 apiece on the BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel